Skip to content
Screener

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.79B+5.7%
Pfizer logo
PfizerPFE
$19.4B+5.8%
Immunome logo
ImmunomeIMNM
$17.08M+55.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.2M-42.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$36M-18.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$112.79M-16.6%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemJune 30, 2026December 31, 2025
Marketable securities402,352365,125
Interest receivable on marketable securities3,8883,285
Total current assets726,432571,519
Property and equipment, net of accumulated depreciation of $1,331 and $1,184, respectively715564
Intangible assets, net of accumulated amortization of $2,777 and $1,856, respectively10,29211,214
Operating lease right-of-use assets3,2403,918
Other non-current assets3,8247,607
Total assets$744,503$594,822

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's PP&E (net)?
Nuvation Bio (NUVB) reported PP&E (net) of $715K in Q2 2026.
How has Nuvation Bio's PP&E (net) changed year-over-year?
Nuvation Bio's PP&E (net) increased by 16.3% year-over-year, from $615K to $715K.
What is the long-term trend for Nuvation Bio's PP&E (net)?
Over 5 years (2020 to 2025), Nuvation Bio's PP&E (net) has grown at a -3.9% compound annual growth rate (CAGR), from $688K to $564K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Nuvation Bio's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude